Wednesday, December 17, 2014 3:00pm-4:30pm EST National Coalition for Cancer Survivorship Post-Training Webinar ©2014 National Coalition for Cancer Survivorship.

Slides:



Advertisements
Similar presentations
Update on Recent Health Reform Activities in Minnesota.
Advertisements

MEDICAL HOME 1/2009 Mary Goldman, D.O., President of MAOFP.
Engaging Patients and Other Stakeholders in Clinical Research
The Rhode Island Chronic Care Sustainability Initiative: Building a Patient-Centered Medical Home Pilot in Rhode Island.
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
Steven D. Vaughn, DVM Director Office of New Animal Drug Evaluation Center for Veterinary Medicine U. S. Food and Drug Administration June 6, 2012 Embracing.
NYS Health Innovation Plan and SIM Testing Grant
© 2014 American Psychiatric Association. All Rights Reserved. Psychiatry and Healthcare Reform Harsh K. Trivedi, MD, MBA Chair, Council on Healthcare Systems.
National Coalition for Cancer Survivorship From Patient to Advocate: Your Role in Improving the United States Cancer Care System Kelsey Nepote, MSW Policy.
1 Wisconsin Partnership Program Steven J. Landkamer Program Manager Wisconsin Dept. of Health & Family Services July 14, 2004.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.
Documentation for Acute Care
Special Topics in IND Regulation
Deploying Care Coordination and Care Transitions - Illinois
A First Look at Meaningful Use Stage 2 John D. Halamka MD.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.5: Unit 5: Financing Health Care (Part 2) 1.5d: Controlling Medical Expenses.
Keith J. Mueller, Ph.D. Director, RUPRI Center for Rural Health Policy Analysis Head, Department of Health Management and Policy College of Public Health.
Presented By Sheila Lucas Ferris State University NURS 511
Decision Support for Quality Improvement
Stakeholder Engagement and Transparency in The Effective Health Care Program Supriya Janakiraman MD MPH AHRQ.
Affiliated with Children’s Medical Services Affiliated with Children’s Medical Services Introduction to the Medical Home Part 2 How does a Practice adopt.
Pharmacy Services.
Perspectives on the Age Wave: Key Issues, Solutions, and Opportunities Robyn Golden, LCSW Director of Older Adult Programs Rush University Medical Center.
Chartered Value Exchanges (CVEs) September 2008 CVEs may wish to tailor this slide deck for use with stakeholders in your community.
PRESENTATION TO THE GOVERNOR’S COMMISSION The Health Care (R)Evolution: How FLHCC Employer Members Are Improving Value and Quality in Health Care Karen.
1 HEALTH CARE REFORM – Changes in Delivery Systems Kenneth W. Kizer, MD, MPH Alaska State Hospital and Nursing Home Association Fairbanks, AK September.
Incentives & Outcomes Committee Draft Recommendations Public Employer Health Purchasing Committee October 25, 2010.
Joe Selby, MD MPH EBRI December 15, 2011 What Might Patient (Employee)- Centered Research Look Like?
1 South Carolina Medicaid Coordinated Care and Enrollment Counselors Programs.
Introduction to Healthcare and Public Health in the US The Evolution and Reform of Healthcare in the US Lecture d This material (Comp1_Unit9d) was developed.
Ms Rebecca Brown Deputy Director General, Department of Health
The Center for Health Systems Transformation
Applying Science to Transform Lives TREATMENT RESEARCH INSTITUTE TRI science addiction Mady Chalk, Ph.D Treatment Research Institute CADPAAC Conference.
HM Modern Hospital Administrator The content 1.Ideal hospital CEO 2.Issues faced by Modern Hospital Administrator.
Bob Doherty Senior Vice President, Governmental Affairs and Public Policy American College of Physicians March 3, 2009 Designing new payment models for.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Maine State Innovation Model (SIM) August 2, 2013.
A Journey Together: New Maryland Healthcare Landscape Health Montgomery Maryland Health Services Cost Review Commission March 2015.
1 The Role of Medicare National Coverage in the Regulatory Process Steve Phurrough MD, MPA Director, Coverage and Analysis Group Centers for Medicare and.
National Strategy for Quality Improvement in Health Care June 15, 2011 Kana Enomoto Director Office of Policy, Planning, and Innovation.
A Journey Together: New Maryland Healthcare Landscape Baltimore County Forum Maryland Health Services Cost Review Commission June 2015.
Presentation to the SAMHSA Advisory Councils
Department of Vermont Health Access The Vermont Approach to Building an Integrated Health System Creating “Accountable Care Partners” Based on Shared Interests.
Improving Patient-Centered Care in Maryland—Hospital Global Budgets
Avalere Health LLC | The intersection of business strategy and public policy Medicare in 2008+: A Framework for Discussion November 2, 2005 Jon Glaudemans.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.9: Unit 9: The evolution and reform of healthcare in the US 1.9d: The Patient.
Delaware PCMH Initiative October Rationale for PCMH Better health quality and outcomes Better health quality and outcomes Lower health care costs.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
What HIT Policy Changes Will Mean for MedTech October 22, 2004 Blair Childs Executive Vice President, Strategic Planning & Implementation.
Learning Outcomes Discuss current trends and issues in health care and nursing. Describe the essential elements of quality and safety in nursing and their.
Primary Care Improvement Infrastructure: The Role of Practice Facilitation Michael L. Parchman, MD MPH MacColl Center for Health Care Innovation AHRQ Annual.
Patient Engagement Today’s presenter:
Practice Transformation for Physicians and Health Care Teams
National Quality Strategy Overview March 2016 Each slide includes notes that you can access by selecting “View” and then “Notes Page” in PowerPoint. Please.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
PREVENTION PLUS Brought to you by:. As of January 1, 2015, CMS has started paying MONTHLY reimbursement for care coordination services to eligible Medicare.
What is Health Literacy? The degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed.
Clinical Trials.
CLINICAL TRIALS.
Patient Centered Medical Home
Industry Perspective: Expanded Access Programs
Clinical Trials — A Closer Look
Expedited Drug Approval Programs
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Speeding access to therapies
Payment Reform to Transform Advanced Illness Care
Designing new payment models for Medical Care: Version 2009 (PCMH) Presentation to The Medical Home Summit Bob Doherty Senior Vice President, Governmental.
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Wednesday, December 17, :00pm-4:30pm EST National Coalition for Cancer Survivorship Post-Training Webinar ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

How FDA Review Activities Affect Cancer Patients Elizabeth Goss ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

FDA and Cancer Patients FDA undertakes four main activities that affect cancer patients: o Determines if protocols submitted under an investigational new drug (IND) application are safe to proceed o Approves cancer drugs and biological products for commercial marketing o Works with pharmaceutical companies to manage production and to address safety issues that arise o Permits access to investigational drugs or biological products on a compassionate use basis ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Standards for Approval To obtain approval of a new drug or biological product, a pharmaceutical manufacturer must: o Demonstrate effectiveness with acceptable safety in adequate and well-controlled clinical trials o Generate information for a product label that: Defines the patient population for treatment with the drug Provides adequate information to enable safe and effective use of the product ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Expedited Review FDA will expedite the review of new products when that is appropriate o May grant “breakthrough therapy” status to promising drugs o May give priority review status to certain therapies o May approve cancer drugs according to accelerated approval standards The investigational cancer therapy must affect a surrogate endpoint other than mortality or irreversible morbidity The surrogate endpoint must be reasonably like to predict clinical benefit Additional studies must be completed to confirm the clinical benefit of the drug ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

FDA and Diagnostic Tests FDA has proposed a plan for regulatory review of tests that are used to diagnose disease or guide treatment Plan is a reversal of long-standing FDA practice of forgoing review of certain diagnostic tests FDA is acting to provide greater assurances about the reliability and utility of tests that diagnose cancer and other diseases and that guide treatment New plan is risk-based; some tests would be subject to minimal review and others to more aggressive review Regulatory plan will be phased in over years Plan is not final but is open for public comment ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Expanded Access and Compassionate Use Expanded Access and Compassionate Use: Means of providing patients access to investigational, or unapproved, therapies Require the engagement of treating physician, FDA, and the company developing the new drug Manufacturers may decline to provide compassionate access for a number of reasons Decisions related to expanded access and compassionate use require a difficult balancing of the needs of the individual and the interests of the community for completion of clinical trials and approval of new drugs ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Discussion Questions Are changes in the compassionate use and expanded access standards necessary to improve responsible access to unapproved therapies for cancer patients? Should incentives be provided to or requirements imposed on drug manufacturers to enhance patient access to unapproved therapies?

Opportunities for Reforming Cancer Care Delivery Shelley Fuld Nasso ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

IOM: Cancer Care in Crisis IOM concluded in 2013 that cancer care is not adequately: o Patient-centered o Accessible o Coordinated o Evidence-based The strains in the system are exacerbated by: o Aging population o Rising cost of cancer care o Complexity of cancer care o Reliance on family caregivers ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Current State of Cancer Care Buy and Bill system and the “business” of medicine o Managing inventory o Using profit margin to fund other services to patients Silos that systematically prevent coordination of care Payment reform models will allow practices to innovate without reliance on volume Patients/survivors/advocates need to be at the table when discussing care delivery improvements ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Discussion Questions How would you change the way the cancer care team interacts with patients? Can you provide advice about how office visits might be changed? How chemotherapy administration might be changed? How cancer treatment side effects are communicated?

©2014 National Coalition for Cancer Survivorship. All Rights Reserved. Current Experiments in New Payment Models Elizabeth Goss

Efforts to Improve Cancer Care General movement away from volume-based care and payment Emphasis on care planning and coordination Reliance on practice guidelines Changes in the processes of care to enhance patient- centeredness (shared decision-making, 24-hour clinical response, prevention of emergency department visits and inpatient admissions) Performance-based payments for providers Quality measures to assess care delivery and patient outcomes ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Incentives and Pressures for Change Practices undertaking reform on their own o Patient-centered oncology medical home Professional societies identifying strategies for reform o Episodes of care CMS Innovation Center has designed a Medicare episode-of-care plan that retains fee-for- service and incorporates payments for practice transformation o Voluntary for private payers o Voluntary for physicians ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Discussion Questions Does the movement away from volume-based care result in less care? Does this change affect quality of care? Are new payment reform systems consistent with the effort to provide personalized cancer care? What level of transparency is necessary in payment reform efforts? o Disclosure of the payment reform effort? Disclosure of performance-based payments? o Disclosure of how the new payment system affects patient costs? ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Measurement of Quality to Protect Patients Shelley Fuld Nasso ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Measurement of Quality to Protect Patients Quality is the right care, at the right time, for the right reason Quality varies and is inadequate within our own system, by provider, state and region Measurement is a way to evaluate and improve care provided by hospitals, doctors, health plans and other health care entities based on accepted national guidelines or evidence Types of measures: process, outcome, patient experience, structural Measures for cancer should be o Understandable, meaningful, and usable by consumers o Outcomes-focused o Based on patient and/or family/caregiver-generated health data ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Symptoms, quality of life and functional status Choose based on value/meaning to patient Standardize methodology, demonstrate reproducibility, gather benchmark standards Examples- o Pain o Nausea o Satisfaction with healthcare providers Patient Reported Outcomes ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Discussion Questions Are current quality assessment measures adequate to assess care and protect patients? What information is meaningful to patients in assessing the quality of cancer care delivered? o Processes of care o Experience of care o Outcomes – survival, quality of life What information should be measured and publicly reported to help patients in choosing providers and hospitals for their cancer care? ©2014 National Coalition for Cancer Survivorship. All Rights Reserved.

Next Steps

Thank You